Avidity begins Cohort C enrollment in FORTITUDE trial Avidity Biosciences has begun enrollment of Cohort C of the Phase 1/2 FORTITUDE™ clinical trial. Below is Avidity’s letter to the FSHD… Read More »
Avidity begins Cohort C enrollment in FORTITUDE trial
“Good Bad Things” is for everyone
by June Kinoshita, FSHD Society “Nothing about us without us” has been the mantra of disability rights advocates for decades, but when it comes to Hollywood, the number of feature… Read More »
Fulcrum halts losmapimod development
Fulcrum halts losmapimod development by June Kinoshita This morning, we received news Fulcrum has decided to halt its development of losmapimod (see press release below). Fulcrum’s decision was based on… Read More »
A note to our families from CEO Mark Stone
A note to our families This morning, Fulcrum released top-line results of its phase 3 trial for Losmapimod. The results showed no difference between placebo and active ingredient groups. Therefore,… Read More »
Remembrance of Lilleen Walters
by Kathryn Wagner, MD PhD I lost my dear friend, Lilleen Walters to FSHD in August. Lilleen and I met approximately 20 years ago when she and her young son,… Read More »